The public issue is entirely an offer-for-sale (OFS) of up to 21.7 million shares by the promoters and other shareholders to the tune of around ₹1,800 crore, said bankers. The company operates under the “Blue Jet” brand offering niche products targeted at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
F&O Talk | Markets remain jittery but downside appears limited: Rahul Ghose
The markets continued to remain under pressure as the Nifty logged its fourth straight week of losses. Although the index attempted a recovery in the
July 27, 2025